ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? Get ProQR Therapeutics alerts:Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $17.99 million 10.98 -$47.73 million ($0.50) -3.75 Artiva Biotherapeutics $250,000.00 1,114.38 -$83.86 million ($3.54) -3.18ProfitabilityProQR Therapeutics has higher revenue and earnings than Artiva Biotherapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Net Margins Return on Equity Return on Assets ProQR Therapeutics -331.33% -84.87% -37.78% Artiva Biotherapeutics N/A -83.31% -70.63%Insider & Institutional Ownership32.7% of ProQR Therapeutics shares are owned by institutional investors. Given ProQR Therapeutics’ higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Artiva Biotherapeutics.